The Fly On The Wall
Breaking News Feed
Fierce Pharma ZIOP and XON CAR-T therapy is expected to be a game changer in the cancer immunotherapy landscape.
GERMANTOWN, Md., BOSTON, and HOUSTON, Jan. 13, 2015 /PRNewswire/ -- Intrexon Corporation (XON), a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology (ZIOP), today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property deveoped at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies.
BrainStorm Cell Therapeutics to Host Conference Call to Discuss Results of Phase 2a Trial of NurOwn™in ALS on January 5, 2015
The New York Times
By Andrew Pollack
December 24, 2014 8:16 pm
Article : I.P.O. of Juno Therapeutics, Developer of a Cancer Treatment, Excites Investors
Juno, based in Seattle, is working on sophisticated treatments that genetically engineer the body’s immune cells so they can better recognize and kill cancer cells and the results have been extraordinary. Some people with leukemia have been rescued from near-certain death. A study of one of Juno’s drfound an 89 percent remission rate among 27 adults with acute lymphoblastic leukemia no longer responding to other treatments
Google: November 18, 2014 FDA Grants Orphan Drug Designation To Juno's JCAR015 Leukemia T Cell Product Candidate
Orphan status for Juno's JCAR015.
Insider Trading Wire
DOUGLAS BRATTON K, of Buys $15,000,000 Worth of $JUNO – #Form4 #InsiderTrading
On 12/24/14, DOUGLAS BRATTON K, reported a net BUY trade of JUNO with a net transaction amountof$15,000,000. Net non-zero shares traded: 625000. See below for more information on with symbol JUNO traded on the Nasdaq NM. Original SEC Filing Period of Report: 2014-12-23
going to $90 to $100
The next big thing in oncology (JUNO )
Juno's lead candidate, JCAR015, is a treatment for acute lymphoblastic leukemia (ALL), the stellar rsults of which led the FDA to grant a breakthrough therapy designation last month, promising an expedited regulatory review.
Wall Street Journal
As High-Cost Treatments Vie, Express Scripts Opts to Use AbbVie’s Over Gilead’s
Express Scripts said the decision will go into effect Jan. 1, and apply to 25 million beneficiaries whose employers contract with the company directly The St. Louis-based company will also encourage all of itscustomers, including those it serves through large health insurers, to make the change, Chief Medical Officer Steve Miller said in an interview. “Many of them will adopt these recommendations,” he said.
The Hottest Biotech IPO of the Year Arrives This Week
December 15, 2014 6:42 AM Adam on Biotech Stocks Follow on Tumblr
Bellicum Pharmaceuticals and Juno Therapeutics are expected to raise more than $300 million combined through their respective initial public offering. Both companies are developing CAR-T therapies, which use re-engineered immune cells to seek out and kill blood cancer cells. Early clinical trials involving this new form of cancer immunotherapy have delivered amazing results and generated huge investor inteest.Other CAR-T companies include Kite Therapeutics and a joint venture between Celgene and Bluebird B